78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in ...
Purple Biotech reports positive trial results for CM24 and NT219, advancing toward biomarker-driven studies and expanding its oncology pipeline. Purple Biotech Ltd. announced positive results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results